{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:22Z","timestamp":1793142742640,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.03.010","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:59:17Z","timestamp":1774461557000},"page":"418-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms"],"prefix":"10.1053","volume":"62","author":[{"given":"Nathalie","family":"Javidi-Sharifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.010_bib0001","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.010_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.010_bib0003","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: a European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.010_bib0004","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.2022017411","article-title":"Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL","volume":"141","author":"Hengeveld","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.010_bib0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.010_bib0006","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.03.010_bib0007","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.03.010_bib0008","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.010_bib0009","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.010_bib0010","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0011","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2023-187943","article-title":"Using peripheral blood (PB) measurable residual disease (MRD) levels to predict <0.01% bone marrow disease (BM uMRD4): identification of effective PB targets for CLL treatment cessation in the ibrutinib plus venetoclax arm of the FLAIR trial","volume":"142","author":"Rawstron","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.03.010_bib0012","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1053\/j.seminhematol.2026.03.010_bib0013","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.010_bib0014","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/bloodadvances.2023011327","article-title":"Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon","volume":"8","author":"Lew","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.010_bib0015","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.03.010_bib0016","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.010_bib0017","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.010_bib0018","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood.2020010146","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.03.010_bib0019","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 22","key":"10.1053\/j.seminhematol.2026.03.010_bib0020","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V128.22.2054.2054","article-title":"Safety and efficacy of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions: final results of the run-in phase of the randomized CLL14 trial (BO25323)","volume":"128","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.03.010_bib0021","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.010_bib0022","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.010_bib0023","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","article-title":"Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia","volume":"35","author":"Letestu","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.010_bib0024","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.seminhematol.2026.03.010_bib0025","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.03.010_bib0026","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136109","article-title":"Five-year analysis of MURANO study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients following fixed-duration venetoclax-rituximab (VenR) therapy (Tx)","volume":"136","author":"Kater","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.010_bib0028","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0029","first-page":"PS1568","article-title":"Using minimal residual disease status to guide venetoclax treatment duration in patients with chronic lymphocytic leukemia: interim results from the phase II VENETOSTOP study","volume":"4160643","author":"Boussi","year":"2025","journal-title":"EHA Library"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.010_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2026.03.010_bib0031","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hon.3163_156","article-title":"MURANO: final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)","volume":"41","author":"Kater","year":"2023","journal-title":"Hematol Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.03.010_bib0032","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.010_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.010_bib0034","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0035","first-page":"EP599","article-title":"Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): phase 3 MURANO substudy","volume":"325359","author":"Wu","year":"2021","journal-title":"EHA Library"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70284","article-title":"Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia","volume":"9","author":"Brander","year":"2025","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0037","first-page":"PF575","article-title":"Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent chronic lymphocytic leukemia (CLL)","volume":"4159982","author":"Davids","year":"2025","journal-title":"EHA Library"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.03.010_bib0038","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.03.010_bib0039","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.010_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.010_bib0041","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0042","first-page":"S155","article-title":"Ibrutinib plus venetoclax with MRD-guided duration of treatment is superior to both continuous ibrutinib monotherapy and FCR for previously untreated CLL: report of the phase III UK FLAIR study","volume":"4159232","author":"Munir","year":"2025","journal-title":"EHA Library"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.03.010_bib0043","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2025029971","article-title":"A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study","volume":"147","author":"Itsara","year":"2026","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.03.010_bib0044","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.010_bib0045","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.010_bib0046","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1053\/j.seminhematol.2026.03.010_bib0047","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0048","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2024-211110","article-title":"Early obinutuzumab significantly increases bone marrow undetectable MRD (10-4 sensitivity) (uMRD4) rate when combined with acalabrutinib and venetoclax in a randomized phase II trial for treatment-na\u00efve CLL","volume":"144","author":"Swaminathan","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.010_bib0049","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.010_bib0050","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"CLL17 Trial Investigators. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.010_bib0051","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0052","first-page":"S156","article-title":"Final analysis of fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"4159233","author":"Wierda","year":"2025","journal-title":"EHA Library"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.010_bib0053","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued long term responses to ibrutinib plus venetoclax treatment for relapsed\/refractory CLL in the Blood Cancer UK TAP CLARITY trial","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood"},{"issue":"30","key":"10.1053\/j.seminhematol.2026.03.010_bib0055","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.010_bib0056","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","volume":"393","author":"Munir","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0057","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2024-211449","article-title":"IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD-defined ibrutinib with venetoclax: report of the UK NCRI FLAIR study","volume":"144","author":"Munir","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0058","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2025-681","article-title":"Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized phase II trial for treatment-na\u00efve CLL","volume":"146","author":"Swaminathan","year":"2025","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.03.010_bib0059","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA arm D results","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.010_bib0060","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0061","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2024-205697","article-title":"Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (\u0394MRD400)","volume":"144","author":"Soumerai","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0062","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2021-148155","article-title":"MAJIC: a phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.010_bib0063","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.010_bib0064","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.03.010_bib0065","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.010_bib0066","first-page":"P616","article-title":"Long-term follow-up update and multivariable analyses of factors associated with duration of response after CD19 CAR T-cell therapy for relapsed\/refractory CLL","volume":"386445","author":"Liang","year":"2023","journal-title":"EHA Library"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.010_bib0067","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0068","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"issue":"10402","key":"10.1053\/j.seminhematol.2026.03.010_bib0069","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0070","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of EPCORE CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.010_bib0071","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2019-121424","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.010_bib0072","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","article-title":"Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL","volume":"9","author":"Soumerai","year":"2025","journal-title":"Blood Adv"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:05:58Z","timestamp":1778727958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000235"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}